Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

NCT04203485 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

762

Enrollment

INDUSTRY

Sponsor class

Conditions

PD-L1 Positive Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Camrelizumab 200mg
DRUG: Apatinib Mesylate 250mg
DRUG: Pemetrexed disodium for injection
DRUG: Paclitaxel injection
DRUG: Carboplatin

Sponsor

Jiangsu HengRui Medicine Co., Ltd.